RBC Capital Initiates Danaher at Outperform With $200 Price Target
The firm expects Danaher’s revenue growth to accelerate to 6% by 2027 amid bioprocess market recovery and end-market improvements. RBC Capital resumed coverage of Danaher Corporation (DHR) with an Outperform rating and a $200 price target, citing a rebound in the bioproces